RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has rescheduled its webcast for Wednesday, April 7 at 10:00 AM Eastern Time. At that time, management will review the results from the recently completed Phase 1B clinical study with PMX-30063, PolyMedix’s novel defensin-mimetic antibiotic.
